A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats

Japanese Journal of Pharmacology

Volumn 71, Issue 4, 1996, Pages 315-323

  Ohnota, Hideki ^a   Kitamura, Tsuyoshi ^a   Kinukawa, Mayumi ^a   Hamano, Shuichiro ^a   Shibata, Nobuo ^a   Miyata, Hiroshi ^a   Ujiie, Arao ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Diabetic complication; Hypoglycemic agent; KAD 1229; Streptozotocin induced non insulin dependent diabetes mellitus (NIDDM) rat

Indexed keywords

ANTIDIABETIC AGENT; CREATININE; GLIBENCLAMIDE; GLICLAZIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MITIGLINIDE; TOLBUTAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATARACT; CELL VACUOLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; GLOMERULUS BASEMENT MEMBRANE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; KIDNEY TUBULE DISORDER; LENS; MICROALBUMINURIA; NEPHROBLASTOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET DISEASE; RAT; RETINA DISEASE; STREPTOZOCIN DIABETES;

EID: 0029796410     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.71.315     Document Type: Article

References (19)

1. Jackson JE and Bressler R: Clinical pharmacology of sulfonyl-urea hypoglyceamic agents (Part 1). Drugs 22, 211-245 (1981)
2. Jackson JE and Bressler R: Clinical pharmacology of sulfonylurea hypoglyceamic agents (Part 2). Drugs 22, 295-320 (1981)
3. Berger W: Incidence of severe side effects during therapy with sulfonylureas and biguanides. Horm Metab Res 17, Supp 15, 111-115 (1985)
4. Jennings AM, Wilson RM and Ward JD: Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 12, 203-208 (1989)
5. Alberti KGMM and Gries FA: Management of non-insulin-dependent diabetes mellitus in Europe: A consensus view. Diabetic Med 5, 275-281 (1988)
6. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA and Cauter EV: Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318, 1231-1239 (1988)
7. Sato Y, Nishikawa M, Shinkai H and Sukegawa E: Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Prac 12, 53-60 (1991)
8. Ohnota H, Koizumi T, Tsutsumi N, Kobayashi M, Inoue S and Sato F: Novel rapid- and short-acting hypoglycemic agent, a calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther 269, 489-495 (1994)
9. Akiyoshi M, Kakei M, Nakazaki M and Tanaka H: A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells. Am J Physiol 268, E185-E193 (1995)
10. + channel by a non-sulfonylurea compound KAD-1229 in a pancreatic β-cell line, MIN 6 cell. Eur J Pharmacol 269, 293-298 (1994)
11. Serradas P, Bailbé D and Portha B: Long-term gliclazide treatment improves the in vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin. Diabetologia 32, 577-584 (1989)
12. Kawai K, Suzuki S, Murayama Y, Watanabe Y and Yamashita K: Comparison of β-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats. Diabetes Res Clin Pract 12, 163-172 (1991)
13. Nishino T, Kodaira T, Shin S, Imagawa K, Shima K, Kumahara Y, Yanaihara C and Yanaihara N: Glucagon radioimmunoassay with use of antiserum to glucagon C-terminal fragment. Clin Chem 27, 1690-1697 (1981)
14. Yue DK, McLennan S, Church DB and Turtle JR: The measurement of glycosylated hemoglobin in man and animals by ammophenylboronic acid affinity chromatography. Diabetes 31, 701-705 (1982)
15. Chasson AL, Grady HJ and Stanley MA: Determination of creatinine by means of automatic chemical analysis. Am J Clin Pathol 35, 83-88 (1961)
16. Ohnota H, Koizumi T, Kobayashi M, Momose Y and Sato F: Normalization of impaired glucose tolerannce by the short-acting hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus rats. Can J Physiol Pharmacol 73, 1-6 (1995)
17. Ohnota H, Miyagi M, Miyata H, Inoue S and Sato F: Characterization of a rapid- and short-acting non-sulfonylurea hypoglycemic agent, KAD-1229. Abstract of 15th International Diabetes Federation Congress, Kobe, 10A5PP1074 (1994)
18. Kinukawa M, Ohnota H and Ajisawa Y: Effect of a non-sulfonylurea hypoglycemic agent, KAD-1229 on hormone secretion in the isolated perfused pancreas of the rat. Br J Pharmacol 117, 1702-1706 (1996)
19. Bonner-Weir S, Trent DF, Honey RN and Weir GC: Responses of neonatal rat islets to streptozotocin. Limited B-cell regeneration and hyperglycemia. Diabetes 30, 64-69 (1981)